Drug Information

Drug General Information
Drug ID
D0SN9T
Former ID
DAP000302
Drug Name
Nilutamide
Synonyms
Anandron; Nilandron; Nilandrone; Nilutamida; Nilutamidum; Aventis Behring Brand of Nilutamide; Aventis Brand of Nilutamide; Hoechst Brand of Nilutamide; Nilutamida [Spanish]; Nilutamidum [Latin]; N 8534; RU 23908; Anandron (TN); Nilandron (TN); RU 23908-10; RU-23908; Nilutamide (USAN/INN); Nilutamide [USAN:BAN:INN]; Nilutamide [USAN:INN:BAN]; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
Drug Type
Small molecular drug
Indication Prostate cancer [ICD9: 185; ICD10:C61] Approved [536387], [539889]
Therapeutic Class
Anticancer Agents
Company
Aventis Pharmaceuticals Inc.
Structure
Download
2D MOL

3D MOL
Formula
C12H10F3N3O4
InChI
InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)
InChIKey
XWXYUMMDTVBTOU-UHFFFAOYSA-N
CAS Number
CAS 63612-50-0
PubChem Compound ID
4493
PubChem Substance ID
10364, 5851647, 7404097, 7848028, 7978498, 8152766, 11111555, 11111556, 11114201, 11342173, 11362356, 11364519, 11367081, 11369643, 11372644, 11374239, 11377805, 11466956, 11468076, 11485861, 11486751, 11487758, 11489789, 11491448, 11492415, 11495439, 12013485, 14850346, 17405438, 24278596, 26612639, 26680190, 26747174, 26747175, 26752242, 29223587, 46505381, 47365306, 47365307, 47959867, 48110544, 48259346, 48259347, 48334600, 49698835, 49980214, 50104947, 50104948, 50104949, 50104950
ChEBI ID
ChEBI:7573
SuperDrug ATC ID
L02BB02
SuperDrug CAS ID
cas=063612500
Target and Pathway
Target(s) Androgen receptor Target Info Antagonist [536659]
KEGG Pathway Oocyte meiosis
Pathways in cancer
Prostate cancer
NetPath Pathway EGFR1 Signaling Pathway
AndrogenReceptor Signaling Pathway
FSH Signaling Pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling
Coregulation of Androgen receptor activity
Regulation of Androgen receptor activity
Nongenotropic Androgen signaling
Regulation of nuclear beta catenin signaling and target gene transcription
FOXA1 transcription factor network
Notch-mediated HES/HEY network
Reactome Nuclear Receptor transcription pathway
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
WikiPathways SIDS Susceptibility Pathways
Integrated Pancreatic Cancer Pathway
Prostate Cancer
Integrated Breast Cancer Pathway
Nuclear Receptors
Androgen receptor signaling pathway
References
Ref 536387Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44.
Ref 539889(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2864).
Ref 536659CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.